Name: ARV-393

Cat#: EX-A8806

Target: PROTACs; BCL6
Pathway: PROTAC; Immunology/Inflammation

Chemical Structure:



Chemical Name	Acetamide, 2-[[6-[[5-chloro-2-[4-[[*trans*-3-[4-[2-(2,6-dioxo-3-piperidinyl)-4-fluoro-2,3-dihydro-1-oxo-1*H*-isoindol-5-yl]-1-piperidinyl]cyclobutyl]oxy]-1-piperidinyl]-4-pyrimidinyl]amino]-1,2-dihydro-1-(1-methylethyl)-2-oxo-3-quinolinyl]oxy]-*N*-methyl- (ACI)

Molecular Weight	898.421	Storage	2 years -20°C powder 1 month -20°C in solvent
Formula	C46H53ClFN9O7		
CAS No.	2851885-95-3	Synonyms	ARV 393; ARV393

Solubility (25°C) *	In vitro	DMSO	DMSO
		Ethanol	N/A
		Water	N/A
	In vivo （should be freshly prepared each time）		

* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Preparing Stock Solutions:

Mass / Volume / Concentration	1 mg	5 mg	10 mg
1 mM	1.1131 mL	5.5653 mL	11.1307 mL
5 mM	0.2226 mL	1.1131 mL	2.2261 mL
10 mM	0.1113 mL	0.5565 mL	1.1131 mL

DMSO : *The above data is based on the product molecular weight 898.42.

Biological Activities:

Description	ARV-393 is a potent and orally active BCL6 PROTAC degrader. ARV-393 induces ubiquitination of BCL6 and its subsequent degradation by the proteasome. ARV-393 has the potential for the research of advanced non-hodgkin lymphoma[1][2][3].
IC_{50} & Target	BCL6[1]
In Vitro	ARV-393 has DC50 and GI50 values of<1 nM in multiple cell lines of diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL)[1] .
In Vivo	ARV-393 (3, 10, 30 mg/kg; po; once daily for 23 days) shows anticancer activity in xenograft model[3] .

References	[1]. Sherman D. Abstract ND05: The discovery of ARV-393, a potent, orally bioavailable BCL6 targeting PROTAC® for the treatment of Non-Hodgkin's Lymphoma[J]. Cancer Research, 2024, 84(7_Supplement): ND05-ND05. [2]. Paolo F. Caimi, et al. Phase 1 Study of ARV-393, a PROTAC BCL6 Degrader, in Advanced Non-Hodgkin Lymphoma. Blood. 2024, 144: 6505. [3]. Paolo Caimi, et al. Abstract PO-010: Trial in Progress: Phase 1 Study of ARV-393, a PROTAC BCL6 Degrader, in Advanced Non-Hodgkin Lymphoma. Blood Cancer Discov. 2024. 5 (3_Supplement): PO-010.